MedTrace Logo

Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

NCT05007262 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-05-09

No results posted yet for this study

Summary

This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.

Conditions

Interventions

DRUG

Tangningtongluo tablets

Four pills each time and three times a day after meals.

DRUG

Calcium dobesilate capsules

1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.

Sponsors & Collaborators

  • Guizhou Bailing Group Pharmaceutical Co Ltd

    lead INDUSTRY

Principal Investigators

  • Junguo Duan, professor · Ineye Hospital of Chendu University of TCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2023-10-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007262 on ClinicalTrials.gov